From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma - PubMed
5 hours ago
- #Lymphoma
- #Immunotherapy
- #Oncology
- Therapeutic landscape for relapsed or refractory large B-cell lymphoma (R/R LBCL) has evolved significantly with cellular therapies, bispecific antibodies, and next-generation antibody-drug conjugates (ADCs).
- Recent randomized studies indicate ADC- and bispecific-anchored regimens outperform legacy chemotherapy, but interpretation is complicated by geographic heterogeneity and selective enrollment.
- Next-generation approaches like bispecific-ADC combinations and dual-target CAR-T constructs aim to address antigen escape and expand curative potential.
- The field faces challenges as therapeutic innovation outpaces evidence infrastructure, requiring updated control arms, harmonized criteria, and adaptive trial platforms.
- The goal is to create biologically rational, accessible pathways to achieve chemotherapy-free cures for R/R LBCL patients.